The content on this site is intended for healthcare professionals only
Dr Bernard Fox speaks to ecancer about the development of an anti-coronavirus vaccine using cancer research strategies.
He explains that the product, developed by OncoSec, wasn't initially designed as a vaccine but was intended to augment the immune response at the tumour site in cancer patients.
Dr Fox explains that his academic lab at the Earle A. Chiles Research Institute (Providence Cancer Institute) had been collaborating with OncoSec to study this treatment before now moving on to continue development to aid the medical need of COVID-19.
He explains how the treatment has been repurposed and also the methodology of the project testing the vaccine in individuals.
Dr Fox goes on to detail the timeline of the development of the vaccine and is hopeful that they will be able to start vaccinating people in May.
Prostate cancer
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer
Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC
Initial results from a phase 1 dose escalation trial of E-602 shows efficacy in solid tumours
Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours
T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable and/or mBC previously treated with T-DM1
